Brief: Pharnext Closes 15 Million Euros Financing From CB Lux
24/01/2019 06:34
24 Jan (Reuters) - PHARNEXT SA PHARN.PA :
* ANNOUNCED ON WEDNESDAY A 15 MILLION EUROS FINANCING FROM
CB LUX
IN THE FORM OF ISSUANCE OF 1.02 MILLION NEW SHARES
* FUNDING WILL PROVIDE PHARNEXT WITH ADDITIONAL MEANS TO
ADVANCE
PXT3003 DEVELOPMENT TOWARDS COMMERCIALISATION FOR THE TREATMENT
OF CHARCOT-MARIETOOTH DISEASE TYPE 1A
Source text for Eikon: urn:newsml:reuters.com:*:nEQ9vpv5ca
Further company coverage: PHARN.PA
(Gdynia Newsroom)
((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Pharnext SCA
See all newsBrief: Pharnext Progresses On Charcot-Marie-Tooth Disease Study
Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A
Brief: Pharnext Receives Offer Valuing Its Drug Candidate For Charcotmarie-Tooth Disease At Over Eur 500 Mln
Brief: Pharnext Appoints Dr Gilbert Wagener As Chief Medical Officer
Brief: Pharnext Reports Significant Progress In Search For Pharmaceutical Partners To Finance Its Development